VIVES is a multi-sector fund that invests in projects with a positive societal impact
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models.
With the...
e-Peas stands for Electronic Portable Energy Autonomous Systems.
The company was founded in 2014 on the conviction that the trillions of connected IoT nodes that will be deployed in the next few...
IntoPIX is an independent and innovative technology provider with world-class expertise and knowledge in video processing and compression, cryptography, high performance computing and microelectronics...
Willem de Vos, Professor at University of Wageningen ; Patrice Cani, Professor at UCLouvain ; Jean-Christophe Malrieu, CEO A-Mansia :
"As founders and CEO of A-mansia Biotech we experienced essential...
Issam Doghri, professor at UCLouvain and co-founder of e-Xstream engineering:
"I developed a first version of a software (Digimat- for digital materials) and I was thinking about ways to make it...
Pierre Delatte, CTO and co-founder of CISSOID :
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the...
Eligo welcomes genetic medicines leader Bobby Gaspar as chair of its board of directors
Oct 1, 2024
Dr. Gaspar brings invaluable expertise to gene-editing pioneering company Eligo as it prepares
Generare raises €5m to scale the discovery of new medicines and molecules hiding in microbes
BiocSol secures €5.2M seed funding to transform sustainable crop protection with next generation microbial-based solutions, targeting total €10M in funding by year-end